MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Income Overview
Net Income
-$738,391
EPS
-$0.03
Unit: Dollar
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Income Statement
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Selling, general and administrative expenses
503,778
751,998
783,640
798,253
Research and development expenses
22,707
33,100
29,058
29,890
Stock-based compensation
253,041
787,374
1,386,213
1,136,217
Total operating expenses
779,526
1,572,472
2,198,911
1,964,360
Loss from operations
-779,526
-1,572,472
-2,198,911
-1,964,360
Interest income
683
3,765
81,606
47,287
Interest expense
42,323
49,377
32,551
30,959
Operating sublease income
17,207
12,000
-64,053.25*
29,680
Gain (loss) on foreign exchange
11,378
-51,156
-91,229
-112,553
Loss on investment in equity securities
-24,766
-31,416
-48,189.75*
-
Loss on impairment of equity investment
-
-
-652,979
-54,235
Other income (expenses)
6,866
-1,281
-10,156
2,194
Total other expenses
-30,955
-117,465
-817,552
-118,586
Loss before provision income tax
-810,481
-1,689,937
-3,016,463
-2,082,946
Provision for income tax expense (benefit)
-
-
0
527
Net loss
-810,481
-1,689,937
-3,016,463
-2,083,473
Net loss attributable to noncontrolling interests
-73,547
-129,695
-249,469
-41,010
Net loss attributed to abvc and subsidiaries
-736,934
-1,560,242
-2,766,994
-2,042,463
Foreign currency translation adjustment
-1,457
12,048
554
3,236
Comprehensive loss
-738,391
-1,548,194
-2,766,440
-2,039,227
Basic EPS
-0.03
-0.06
-0.138
-0.09
Diluted EPS
-0.03
-0.06
-0.138
-0.09
Basic Average Shares
26,058,884
25,448,516
20,108,944*
23,256,590
Diluted Average Shares
26,058,884
25,448,516
20,108,944*
23,256,590
Page 1
Unit: Dollar. Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Income Statement
Comprehensive loss
-$738,391
(66.70%↑ Y/Y)
Net loss attributed
to abvc and...
-$736,934
(67.35%↑ Y/Y)
Foreign currency
translation adjustment
-$1,457
(-103.68%↓ Y/Y)
Net loss
attributable to...
-$73,547
(2.99%↑ Y/Y)
Net loss
-$810,481
(65.26%↑ Y/Y)
Loss before
provision income tax
-$810,481
(64.90%↑ Y/Y)
Loss from operations
-$779,526
(66.03%↑ Y/Y)
Total other expenses
-$30,955
(-117.64%↓ Y/Y)
Operating sublease income
$17,207
(43.39%↑ Y/Y)
Gain (loss) on
foreign exchange
$11,378
(-91.64%↓ Y/Y)
Other income
(expenses)
$6,866
(195.63%↑ Y/Y)
Interest income
$683
(-96.43%↓ Y/Y)
Total operating
expenses
$779,526
(-66.03%↓ Y/Y)
Interest expense
$42,323
(-67.30%↓ Y/Y)
Loss on investment in
equity securities
-$24,766
(44.86%↑ Y/Y)
Selling, general and
administrative expenses
$503,778
(-27.00%↓ Y/Y)
Stock-based compensation
$253,041
(-83.90%↓ Y/Y)
Research and development
expenses
$22,707
(-31.76%↓ Y/Y)
Buy us a coffee
ABVC BIOPHARMA, INC. (ABVC)
ABVC BIOPHARMA, INC. (ABVC)